Upstream Bio (NASDAQ:UPB) Coverage Initiated at William Blair

Research analysts at William Blair assumed coverage on shares of Upstream Bio (NASDAQ:UPB) in a research report issued on Tuesday, MarketBeat Ratings reports. The firm set an “outperform” rating on the stock.

Separately, TD Cowen initiated coverage on shares of Upstream Bio in a report on Tuesday. They set a “buy” rating on the stock.

Upstream Bio Trading Down 3.0 %

NASDAQ UPB opened at $26.57 on Tuesday. Upstream Bio has a 52 week low of $20.74 and a 52 week high of $29.46.

Insider Activity at Upstream Bio

In related news, major shareholder Ai Upstream Llc purchased 1,175,000 shares of the stock in a transaction that occurred on Tuesday, October 15th. The stock was acquired at an average cost of $17.00 per share, with a total value of $19,975,000.00. Following the transaction, the insider now owns 1,175,000 shares of the company’s stock, valued at $19,975,000. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Erez Chimovits purchased 825,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 15th. The shares were acquired at an average cost of $17.00 per share, for a total transaction of $14,025,000.00. Following the completion of the acquisition, the director now owns 4,554,873 shares in the company, valued at $77,432,841. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Ai Upstream Llc acquired 1,175,000 shares of Upstream Bio stock in a transaction on Tuesday, October 15th. The stock was purchased at an average cost of $17.00 per share, with a total value of $19,975,000.00. Following the completion of the transaction, the insider now directly owns 1,175,000 shares in the company, valued at $19,975,000. The disclosure for this purchase can be found here.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.